Published in Br J Cancer on November 16, 2001
Hypoxia-inducible factor-2α regulates GM-CSF-derived soluble vascular endothelial growth factor receptor 1 production from macrophages and inhibits tumor growth and angiogenesis. J Immunol (2011) 0.98
Clinical uses of GM-CSF, a critical appraisal and update. Biologics (2008) 0.97
Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol (2012) 0.86
Relative Efficacy of Granulocyte-Macrophage Colony-Stimulating Factor, Dacarbazine, and Glycoprotein 100 in Metastatic Melanoma: An Indirect Treatment Comparison. Adv Ther (2016) 0.75
Reporting results of cancer treatment. Cancer (1981) 28.83
Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A (1993) 11.95
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis (1961) 4.25
The granulocyte-macrophage colony-stimulating factors. Science (1985) 4.13
Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods (1996) 3.80
Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science (1986) 2.84
Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor. J Clin Oncol (2000) 2.37
Hematopoietic growth factors. J Clin Invest (1987) 2.11
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol (1998) 2.06
Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int J Cancer (1996) 1.76
Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood (1996) 1.66
Novel responses of human skin to intradermal recombinant granulocyte/macrophage-colony-stimulating factor: Langerhans cell recruitment, keratinocyte growth, and enhanced wound healing. J Exp Med (1992) 1.58
Recombinant human GM-CSF enhances T cell-mediated cytotoxic function after ABMT for hematological malignancies. Bone Marrow Transplant (1993) 1.45
Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant. Cancer Res (2001) 1.35
Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. Blood (1998) 1.35
Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol (1998) 1.32
GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood (1989) 1.25
Amplification of IL-2-driven T cell proliferation by recombinant human IL-3 and granulocyte-macrophage colony-stimulating factor. J Immunol (1988) 0.95
Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. Melanoma Res (1996) 0.92
Granulocyte-macrophage colony-stimulating factor protects dendritic cells from liposome-encapsulated dichloromethylene diphosphonate-induced apoptosis through a Bcl-2-mediated pathway. Eur J Immunol (1999) 0.88
Regulation of MHC class II gene expression in macrophages by hematopoietic colony-stimulating factors (CSF). Induction by granulocyte/macrophage CSF and inhibition by CSF-1. J Exp Med (1989) 0.88
Recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF) and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma. J Immunother (1999) 0.86
Optimization of peripheral blood stem cell mobilization. Stem Cells (1996) 0.83
GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation. Bone Marrow Transplant (1996) 0.82
Effect of monoclonal antibody 17-1A and GM-CSF in patients with advanced colorectal carcinoma--long-lasting, complete remissions can be induced. Int J Cancer (1993) 0.82
Medical management of stage IV malignant melanoma. Medical issues. Cancer (1995) 0.81
Granulocyte-macrophage colony-stimulating factor inhibits tumour growth. Br J Surg (1993) 0.78
Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas? Ann Oncol (1997) 0.77
In vitro immunization of patient T cells with autologous bone marrow antigen presenting cells pulsed with tumor lysates. Int J Cancer (2000) 0.77
Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgramostim enhance antisarcoma therapy? J Natl Cancer Inst (1994) 0.77
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Mutation spectrum and genotype-phenotype analyses in Cowden disease and Bannayan-Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet (1998) 4.72
Localization of the gene for Cowden disease to chromosome 10q22-23. Nat Genet (1996) 3.53
Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst (1995) 3.00
Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol (1999) 2.34
Prognostic factors in retroperitoneal sarcoma: a multivariate analysis of a series of 165 patients of the French Cancer Center Federation Sarcoma Group. Cancer (2001) 2.25
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol (2008) 2.10
Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial. J Clin Oncol (1998) 2.06
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03
Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br J Cancer (1999) 1.96
Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). Ann Oncol (1999) 1.74
Imatinib for progressive and recurrent aggressive fibromatosis (desmoid tumors): an FNCLCC/French Sarcoma Group phase II trial with a long-term follow-up. Ann Oncol (2010) 1.58
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol (2007) 1.54
Analysis of the 10q23 chromosomal region and the PTEN gene in human sporadic breast carcinoma. Br J Cancer (1999) 1.54
A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors. Ann Oncol (2008) 1.44
Allelic imbalance, including deletion of PTEN/MMACI, at the Cowden disease locus on 10q22-23, in hamartomas from patients with Cowden syndrome and germline PTEN mutation. Genes Chromosomes Cancer (1998) 1.43
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology (2001) 1.37
Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study. J Clin Oncol (1992) 1.37
High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol (1998) 1.37
Systemic lupus erythematosus syndrome induced by pindolol. Br Med J (1979) 1.32
Chemotherapy in patients with desmoid tumors: a study from the French Sarcoma Group (FSG). Ann Oncol (2011) 1.29
Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer (2000) 1.29
Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood (2000) 1.27
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol (2008) 1.18
Alterations in the human immune response to the hepatitis B vaccine among the elderly. Cell Immunol (1987) 1.17
Differential effect of Rac and Cdc42 on p38 kinase activity and cell cycle progression of nonadherent primary mouse fibroblasts. J Biol Chem (2000) 1.16
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol (1999) 1.14
Influence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, phase III trial. Ann Oncol (2012) 1.11
Cryoglobulinemic neuropathy: a pathological study. Ann Neurol (1980) 1.07
The gene for a new brain specific RhoA exchange factor maps to the highly unstable chromosomal region 1p36.2-1p36.3. Oncogene (2001) 1.06
Identification of biological factors predictive of response to imatinib mesylate in aggressive fibromatosis. Br J Cancer (2010) 1.05
Dendritic cells issued in vitro from bone marrow produce PGE(2) that contributes to the immunomodulation induced by antigen-presenting cells. Cell Immunol (2001) 1.04
Summary of the Standards, Options and Recommendations for the use of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose (FDP-PET scanning) in oncology (2002). Br J Cancer (2003) 1.03
The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens (2005) 1.03
Hepatitis-B vaccination in the elderly. J Infect Dis (1984) 1.03
Mutations of PTEN in patients with Bannayan-Riley-Ruvalcaba phenotype. J Med Genet (1998) 1.01
Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res (2000) 1.00
Effect of lipoxygenase metabolites of arachidonic acid on proliferation of human T cells and T cell subsets. J Immunol (1985) 0.99
Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int J Cancer (2000) 0.98
A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood (1998) 0.97
Radiological features of triple-negative breast cancers (73 cases). Diagn Interv Imaging (2012) 0.96
HL-A and silicosis. Am Rev Respir Dis (1977) 0.96
Second non-germ cell malignancies in patients treated for stage I-II testicular seminoma. Radiother Oncol (1999) 0.95
[Metastasis on previous hip arthroplasty: three cases]. Rev Chir Orthop Reparatrice Appar Mot (2005) 0.94
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J Clin Oncol (1999) 0.94
Retroperitoneal sarcomas: patterns of care at diagnosis, prognostic factors and focus on main histological subtypes: a multicenter analysis of the French Sarcoma Group. Ann Oncol (2014) 0.93
[Male breast cancer: a review of 52 cases collected at the Institute Bergonié (Bordeaux, France) from 1980 to 2004]. Gynecol Obstet Fertil (2008) 0.92
Radiosurgery without whole brain radiotherapy in melanoma brain metastases. Club de Cancérologie Cutanée. Eur J Cancer (1998) 0.91
[Eccrine porocarcinoma: a highly malignant tumor with a poor prognosis]. Ann Dermatol Venereol (2008) 0.91
Dendritic cells produce eicosanoids, which modulate generation and functions of antigen-presenting cells. Prostaglandins Leukot Essent Fatty Acids (2002) 0.90
Detection of local recurrences of limb soft tissue sarcomas: is magnetic resonance imaging (MRI) relevant? Eur J Radiol (2009) 0.89
Metabolism of polyunsaturated fatty acids by mouse peritoneal macrophages: the lipoxygenase metabolic pathway. Agents Actions (1981) 0.89
Leukemia inhibitory factor: part of a large ingathering family. Int Rev Immunol (1998) 0.89
Efficacy of lenograstim on hematologic tolerance to MAID chemotherapy in patients with advanced soft tissue sarcoma and consequences on treatment dose-intensity. J Clin Oncol (1995) 0.89
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO). Invest New Drugs (2013) 0.89
Functional characterization of liver-associated lymphocytes in patients with liver metastasis. Gastroenterology (1993) 0.89
High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol (2011) 0.89
Population pharmacokinetics of total and unbound etoposide. Cancer Chemother Pharmacol (1998) 0.89
Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin Endocrinol (Oxf) (2007) 0.88
Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat (2008) 0.88
Detection of t(2;5)(p23;q35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Pathol (1996) 0.88
Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Français d'Immunothérapie. J Clin Oncol (1998) 0.88
Role of thymus-eicosanoids in the immune response. Prostaglandins Leukot Essent Fatty Acids (1992) 0.87
White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma. Clin Cancer Res (2000) 0.87
[Results of a randomized study comparing combination of navelbine-cisplatin to combination of vindesine-cisplatin and to navelbine alone in 612 patients with inoperable non-small cell lung cancer]. Bull Cancer (1996) 0.86
Widespread cutaneous carcinomas associated with human papillomaviruses 5, 14 and 20 after introduction of methotrexate in two long-term PUVA-treated patients. Dermatology (2001) 0.86
Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity. Breast Cancer Res Treat (2012) 0.86
A monoclonal antibody based elisa for quantitation of human leukaemia inhibitory factor. Cytokine (1997) 0.86
The Spectrum of Cutaneous Lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol (1999) 0.86
Effects of prostaglandin E2 and preincubation on lectin-stimulated proliferation of human T cell subsets. Cell Immunol (1982) 0.86
Reference method for detection of Pgp mediated multidrug resistance in human hematological malignancies: a method validated by the laboratories of the French Drug Resistance Network. Cytometry (1998) 0.85
Follicular lymphomas--a review of treatment modalities. Crit Rev Oncol Hematol (2000) 0.85
Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Experience of the French Study Group. Cancer Chemother Pharmacol (1990) 0.85
Fluorodeoxyglucose positron emission tomography fails to detect distant metastases at initial staging of melanoma patients with metastatic involvement of sentinel lymph node. Br J Dermatol (2011) 0.84
[An individualized prognosis for truncal melanoma? A series of 77 cases]. Bull Cancer (2010) 0.84
[Diagnosis and treatment of soft-tissue tumors]. Rev Chir Orthop Reparatrice Appar Mot (2006) 0.84
Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol (2012) 0.84
Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas. Blood (1999) 0.84
[Radiosensitization induced by vemurafenib]. Cancer Radiother (2013) 0.84
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon? Target Oncol (2009) 0.83
The retrospective binning method improves the consistency of phase binning in respiratory-gated PET/CT. Phys Med Biol (2012) 0.83
Germ cell tumors in patients infected by the human immunodeficiency virus. Cancer (2001) 0.83
A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer (2000) 0.83
Retroperitoneal soft tissue sarcomas: a pilot study of intraoperative radiation therapy. J Surg Oncol (1996) 0.83
A phase II trial of panobinostat in patients with advanced pretreated soft tissue sarcoma. A study from the French Sarcoma Group. Br J Cancer (2013) 0.83
Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma. Eur J Cancer (2001) 0.83
Modulation of cisplatin cytotoxicity by human recombinant interferon-gamma in human ovarian cancer cell lines. Eur J Cancer (1994) 0.82
Relevance of vertical growth pattern in thin level II cutaneous superficial spreading melanomas. Am J Surg Pathol (2003) 0.81
Effect of LTB4 on the inhibition of natural cytotoxic activity by PGE2. Cell Immunol (1992) 0.81
Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Int J Gynecol Cancer (2008) 0.81
Neoadjuvant tamoxifen for hormone-sensitive non-metastatic breast carcinomas in early postmenopausal women. Ann Oncol (2002) 0.81
Rapidly lethal dermatomyositis associated with metastatic melanoma. J Eur Acad Dermatol Venereol (2008) 0.81
Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas. J Invest Dermatol (2001) 0.81
HILDA/LIF urinary excretion during acute kidney rejection. Transplantation (1992) 0.81
Induction of suppressor cells from peripheral blood T cells by 15-hydroperoxyeicosatetraenoic acid (15-HPETE). J Immunol (1985) 0.81